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Abstract
Traditionally, the number of citations that a scholarly paper receives from other papers is used as the
proxy of its scientific impact. Yet citations can come from domains outside the scientific community, and
one such example is through patented technologies—paper can be cited by patents, achieving technological
impact. While the scientific impact of papers has been extensively studied, the technological aspect remains
less known in the literature. Here we aim to fill this gap by presenting a comparative study on how 919
thousand biomedical papers are cited by U.S. patents and by other papers over time. We observe a positive
correlation between citations from patents and from papers, but there is little overlap between the two
domains in either the most cited papers, or papers with the most delayed recognition. We also find that
the two types of citations exhibit distinct temporal variations, with patent citations lagging behind paper
citations for a median of 6 years for the majority of papers. Our work contributes to the understanding of
the technological impact of papers.
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1. Introduction
Scientific research builds upon existing knowledge, and such reliance is often manifested by citing previous
scientific papers. Citation flows among papers therefore have long been used to study the scientific enterprise,
such as mapping knowledge domains (Rosvall & Bergstrom, 2008), tracking the evolution of science and the
emergence of new fields (Rosvall & Bergstrom, 2010; Sinatra et al., 2015), understanding the formation of
scientific consensus (Shwed & Bearman, 2010), allocating credit in science (Shen & Baraba´si, 2014), among
many others. Citation-based metrics have been increasingly adopted to assess the scientific impact of various
entities in the scientific community, from papers (Wang et al., 2013) and authors (Hirsch, 2005; Sinatra et al.,
2016) to journals (Stigler, 1994; Varin et al., 2016), institutions (Davis & Papanek, 1984), and nations (King,
2004). Yet scholarly papers can have their impact that reaches domains beyond the scientific community.
Here, we focus on one such domain—patented technologies—to study the technological impact of papers, as
patents are the most widely used ones to represent technological advance (Fleming & Sorenson, 2004; Meyer,
2002). Although such representation is limited by the possibility that not all patentable inventions have
been patented, scholars have long used patent data to understand innovative activities and the development
of technologies.
Papers that are cited by a patent are listed in the non-patent references (NPRs) section of a patent
application and considered relevant to the application by either the applicant or the patent examiner. Apart
from papers, many other types of documents may also be listed as NPRs, such as books, Web pages, etc.
Patent law imposes an obligation on patent applicants to submit relevant “prior art” of which they are
aware, including both patents and non-patent materials, and failure to do so may result in the application
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unpatentable. Patent examiner who reviews the application may find prior art themselves, generating
additional citations, and then determines the patentability of the invention.
Studies about the analysis of patent-to-paper citation linkages started already in the 1980s. Narin &
Olivastro (1992) reported a statistical analysis on the types of NPRs and the time and nation dimension of
scientific NPRs. Scholars have proposed several interpretations about the patent-to-paper citation linkages.
One of the most adopted ones is that the linkage signals direct knowledge flows (Jaffe et al., 1993; Azoulay
et al., 2011), that is, the occurrence of citations to a patent or a paper is argued to indicate that the inventors
have benefited from the patent or the paper. This interpretation, although subject to debate (Meyer, 2000)
and limited by the fact that patent examiners can also add citations (Alca´cer & Gittelman, 2006; Alca´cer
et al., 2009; Lemley & Sampat, 2012), has been the basis of many studies that attempt to demonstrate how
publicly-financed research contributes to technological advances and private-sector innovations (Narin et al.,
1997; McMillan et al., 2000; Ahmadpoor & Jones, 2017; Azoulay et al., 2017; Li et al., 2017), motivating
further public support for scientific research. Fleming & Sorenson (2004) argued that the mechanism through
which science increases the rate of invention is that science leads inventors’ search process more directly to
useful combinations. Other scholars have argued that patent-to-paper citations signal relatedness between
science and technology (Callaert et al., 2014).
Our work shifts the attention from interpreting the linkage to assessing the technological impact of
papers. In this regard, a related line of literature is the examination of the broader impact of research
beyond the traditional scientific community. Existing work has examined how papers are covered by news
media (Phillips et al., 1991), used in the development of drug products (Williams et al., 2015), referenced in
clinical guidelines (Grant et al., 2000), and mentioned on the social Web (e.g., Twitter and Wikipedia) (Thel-
wall et al., 2013), among many other outlets. Our work extends this line of literature by focusing on the
technological community, which hitherto has been less explored, and investigates how papers are cited by
patents. Moreover, we emphasize citation growth over time rather than simple citation counts at a partic-
ular time point, allowing us to explore the dynamics of the utilization of scientific research for technology
development. The only study that is similar to our work is the one by Ding et al. (2017). However, we not
only look at the entire citation history of papers as opposed to two five-year time windows considered by
them, but also make a comparison of citations received from patents and from papers.
Based on the cohort of biomedical papers that have received citations from U.S. patents, we perform
a comparative study on how they are cited by patents and by other papers over time. We report a set of
stylized facts about the two types of citations. First, similar to paper citations, patent citations are also
heterogeneously distributed. Yet, highly-cited papers in the two domains have small overlap. Second, there
are delayed-recognition papers that achieve high popularity among patents after years of dormant. Third,
patent citations generally lag behind paper citations for the majority of papers.
2. Data and methods
For each paper, we assembled two types of citations, namely those from other papers and from patents.
We first describe the patent citation case. We focused only on U.S. patents, due to the public availability
of patent bibliographic data over a long period of time. To get citation information from patents, we down-
loaded the front page bibliographic data of all utility patents granted by the United States Patent and Trade-
mark Office (USPTO) between 1976 and 2013 from https://bulkdata.uspto.gov, and excluded withdrawn
patents (https://www.uspto.gov/patents-application-process/patent-search/withdrawn-patent-numbers).
Each patent included a list of references containing previously issued patents and optional NPRs that can
refer to essentially anything, including books, papers, patent applications, online resources, etc. As we are
interested in papers, we further excluded patents without any NPR, ending up with 1, 637, 072 patents.
We then matched their NPRs with papers indexed in MEDLINE, a large-scale bibliographic database
for biomedical research literature maintained by the National Library of Medicine (NLM). The matching
steps are as follows:
1. We submitted a search query to PubMed where the search term is the entire NPR text, with the URL
following: https://www.ncbi.nlm.nih.gov/pubmed/?term=[NPR]&report=uilist&format=text, which
returned the matched PMID.
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Table 1: Confusion matrix for results of matching non-patent references to MEDLINE papers.
True positive = 117 False positive = 0
False negative = 6 True negative = 85
2. If the first step failed, we then extracted relevant bibliographic information, such as author, title,
journal, volume, number, pages, and year, available in the NPR text, using the AnyStyle parser
(https://anystyle.io/). It employs a machine learning technique called Conditional Random Fields
to parse citation text with any style, which is achieved by pre-training the model with different styles
of labeled citation text.
3. After the extraction, we searched PubMed using the ECitMatch E-utility (https://dataguide.nlm.
nih.gov/eutilities/utilities.html#ecitmatch), which accepts 5 types of information as input,
namely journal, year, volume, first page, and author name, and returns the matched PMID. When
searching, we first used all the 5 fields and, if failed, all the 5 possible combinations of 4 fields.
To validate our matching results, we manually matched 208 randomly selected NPRs, and Table 1 reports
the confusion matrix. For 117 cases, hand labeling and the matching method found the same paper (true
positives); for 85 cases, both agreed that there was no paper matched (true negatives); and for 6 cases, our
matching method deemed that there was no paper matched but manual labeling found one (false negatives).
A total of 919, 222 unique papers were matched.
After this integration step, we counted, for a paper published in calendar year tp, the number of patent
citations it received in the t-th (t ∈ [0, L]; L = T − tp; T = 2013) year after its publication, denoted as
cPt . Note that the citing patents in each year t (calender year tp + t) are those issued at time t rather than
those whose applications were submitted at t. The total number of patent citations it received until the end
of the observation period is CP =
∑T−tp
t=0 c
P
t . Here we do not distinguish between citations generated by
applicants or examiners, as we do not concern about knowledge spillover and examiner-added citations may
also indicate the impact of papers.
To get the number of citations from papers, we turn to the Web of Science (WoS) database, as citation
data is available only for PubMed Central papers. We used a version of WoS currently housed at the Indiana
University Network Science Institute to retrieve the paper citation data. To locate MEDLINE papers in
WoS, we used the mapping data between PMID (PubMed ID) and UT (Accession Number), which are the
two identifiers used in their respective database, and successfully found 859, 085 (93.46%) MEDLINE papers
in WoS. When counting citations, we only considered the following types of documents: article, review,
editorial, note, and letter. For each of the papers under consideration, we denote its yearly number of
citations from other papers as cAt , and C
A is the total number of paper citations it received by 2013.
For analysis that involved the entire MEDLINE database, we used a snapshot in 2015 that contained
23, 343, 329 papers. To get the fields of papers, we chose to use the NLM Catalog data (https://www.ncbi.
nlm.nih.gov/nlmcatalog), as it is specifically created to be used in conjunction with other databases such
as MEDLINE maintained by NLM. It assigns each indexed journal to one or more categories called Broad
Subject Terms (e.g., Biochemistry, Cell Biology, Nursing, Health Services Research).
3. Results
The overarching goal of the present study is to examine how patent citations of papers are different from
paper citations. To this end, we present four sets of results. First, we report in Section 3.1 descriptive
statistics on the types of papers that get cited by patents, journals where these papers were published, and
fields to which they belong, given that these statistics are not well-known in the existing literature. Second,
in Section 3.2, we examine how total patent and paper citations differ. Next, Section 3.3 examines how
patent and paper citations change over time by focusing on the delayed recognition phenomenon. Finally,
Section 3.4 performs a lead-lag analysis of citation dynamics.
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Table 2: Document type distribution for 859, 085 papers cited by USPTO-issued patents.
Type Count %
Article 744, 309 86.64
Review 63, 709 7.42
Note 29, 344 3.42
Editorial 10, 520 1.22
Letter 8, 544 0.99
Others 2, 659 0.31
3.1. Fields and journals
The 919, 222 papers that get patent citations only account for a very small portion (4%) of all 22, 975, 980
MEDLINE papers published until 2013. Our estimation is similar to the one obtained from a recent study
where papers in WoS rather than MEDLINE were considered: 1.41 out of 32 million, or 4.4% of, WoS papers
were cited by USPTO-issued patents (Ahmadpoor & Jones, 2017).
Table 2 shows the distribution of document types assigned by WoS for the 859, 085 MEDLINE papers
indexed there. Articles contribute to the largest portion (86.6%), followed by review, note, editorial, and
letter.
Table 3 displays the top 20 most cited biomedical research fields, as defined by NLM as Broad Subject
Terms, which in total account for 73.1% of patent citations. For each field, we derived three statistics: (1)
the total number of patent citations of all papers published in journals that belong to the field, (2) the unique
number of papers that are cited by patents, and (3) the fraction of papers that are cited by patents among
all papers published there. While the first two are of retrospective, the third one is of prospective, since
each journal publishes different amounts of papers. Biochemistry is the most cited field, attracting 12.9%
of citations from patents, followed by Science (10.6%), Molecular Biology (6.0%), Allergy and Immunology
(5.2%), Cell Biology (4.2%), and Chemistry (3.7%). Here “Science” covers multi-disciplinary journals like
Nature and Science, similar to the Multidisciplinary Science designated in Journal Citation Reports (JCR).
The second observation from Table 3 is that the share of citations for each field is roughly proportional
to the share of the number of unique papers cited, except for the Science category. This means that multi-
disciplinary journals accrue patent citations disproportionately, suggesting a larger-than-average number of
patent citations for papers published there.
When looking at the fraction of cited papers among all papers published (“% Published” column), we
observe that the overall tendency to be cited by patents varies across fields. Among these most cited fields,
Biotechnology has the largest portion (14%) of papers cited by patents. Virology, Biochemistry, Molecular
Biology, Allergy and Immunology, and Cell Biology all have more than 10% of such papers. On the other
hand, only 1.7% of papers belonging to Medicine get patent citations, which is similar for General Surgery.
Cardiology, Neurology, Biology, and Physiology also generate a small fraction of patent-cited papers.
The last column in Table 3 indicates whether these fields belong to basic research or clinical medicine, as
categorized by Narin et al. in the 1976 pioneering work on the structure of biomedical literature (Narin et al.,
1976). Although the number of basic research fields is similar to the ones belonging to clinical medicine,
basic research surpass clinical medicine once we weight by total citations or unique papers. This resonates
with previous results (Narin et al., 1997; McMillan et al., 2000).
Next, we delve into journals. Table A.1 reports the top 10 field-specific journals that received the most
patent citations. For each journal, we present the same set of statistics as in Table 3. We see from Table A.1
that papers that obtained patent citations were published in leading journals. Across fields, PNAS, Journal
of Biological Chemistry (JBC), a journal with a long publishing history, and Science are the top three
most cited journals. They are also the three journals that published the largest number of papers that are
cited by patents. Other highly-cited journals include Nature, Journal of Medicinal Chemistry, Nucleic Acids
Research, and Cell.
Similar to what has been observed in Table 3, most journals attract patent citations proportionate to
their share of cited papers. But this is not the case for Cell : only 15% of Cell Biology papers were published
4
Table 3: List of top 20 most cited fields. For each field, as defined by NLM as Broad Subject Term, we counted the total
number of patent citations of papers published in journals that belong to the field, as well as the unique number of papers
cited by patents and the fraction of these papers among all papers in this field. Journals that are designated to multiple fields
are counted multiple times. “Science” covers multi-disciplinary journals.
Field # Cites % Cites # Papers % Papers % Published Category
Biochemistry 603, 322 12.86 143, 381 12.26 11.58 Basic
Science 495, 804 10.57 57, 054 4.88 9.64 –
Molecular Biology 282, 126 6.02 62, 826 5.37 11.19 Basic
Allergy and Immunology 243, 044 5.18 58, 866 5.03 11.09 Clinical
Cell Biology 198, 189 4.23 41, 998 3.59 10.30 Basic
Chemistry 175, 537 3.74 44, 047 3.77 7.96 –
Pharmacology 167, 290 3.57 46, 249 3.96 7.11 Clinical
Neoplasms 162, 979 3.48 45, 752 3.91 6.64 –
Medicine 158, 470 3.38 38, 109 3.26 1.69 Clinical
Biotechnology 127, 242 2.71 22, 701 1.94 14.04 –
Neurology 101, 226 2.16 32, 322 2.76 3.62 Clinical
Biophysics 97, 713 2.08 27, 627 2.36 6.62 Basic
Virology 83, 114 1.77 20, 188 1.73 13.83 Basic
Physiology 82, 901 1.77 25, 268 2.16 4.25 Basic
Cardiology 82, 898 1.77 19, 875 1.70 3.61 –
Microbiology 78, 376 1.67 25, 299 2.16 6.78 Basic
Ophthalmology 75, 156 1.60 22, 185 1.90 5.74 Clinical
Vascular Diseases 71, 664 1.53 19, 435 1.66 5.14 –
Biology 70, 833 1.51 19, 696 1.68 4.19 –
General Surgery 68, 991 1.47 15, 409 1.32 1.80 Clinical
in Cell, yet they account for 31% of citations to the field. Other prominent examples, although to a lesser
extent, include Nucleic Acids Research, Journal of Medicinal Chemistry, Nature, and Science.
Table A.1 also provides results from a prospective analysis. Across these fields, Annual Review of
Immunology has the highest fraction (54%) of papers that are cited by patents, followed by Journal of
Medicinal Chemistry (43%), Cell (38%), and EMBO Journal (30%). On the other hand, Nature and
Science have a relatively low fraction, which could simply due to the fact that they are multidisciplinary
journals that publish non-biomedical papers.
A final point regarding both Tables 3 and A.1 is that these results are limited by the fact that MEDLINE
is a database for the biomedical research literature. As such, it may have low coverage of papers in other
disciplines such as physics and engineering, especially if papers in these disciplines are not directly related
to biomedicine. This may to some extent dictate our results. For example, in a seminal work by Narin et al.
(1997) that studied citations from U.S. patents to papers, they found that Tetrahedron is among the top
most cited Chemistry journals. However, it fails to make it top in Table A.1, because MEDLINE only has a
limited coverage of papers in Tetrahedron. Future work therefore is needed to compare how our results are
different from the ones based on other databases like WoS.
3.2. Total citations
How many citations does a paper receive from patents? How does it compare to citations from other
papers? In this section, we investigate total citations. Tables A.2 and A.3 list the top 10 papers by total
patent citations CP and paper citations CA, respectively. The paper with the highest number of paper
citations in our sample happens to be the most cited one of all time (Noorden et al., 2014).
Heterogeneity in the number of patent citations CP is present for the cohort of 919, 222 papers that got
cited by patents, as evidenced from Fig. 1A where we plot the survival distribution of CP . Although 414, 981
(45.1%) papers have only one patent citation, there exists papers that are cited by thousands of patents.
We fitted the distribution with the power-law function, giving us exponent αP = 2.93. For comparison, we
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Figure 1: Patent and paper citation statistics. (A) Survival distribution functions of total number of patent citations CP and
paper citations CA across all papers that are cited by at least one U.S. patent (CP ≥ 1). Both CP and CA are measured until
2013. The red dashed line corresponds to the estimation of the power-law distribution p(CP ) = α
P−1
CPmin
(
CP
CPmin
)−αP
, where
CPmin = 45 and α
P = 2.93. The blue dashed line is the power-law fit of CA, where CAmin = 1344 and α
A = 3.01. Both are
estimated using the method developed in Alstott et al. (2014) and Clauset et al. (2009). (B) Heat map between log10(C
A + 1)
and log10 C
P . The color encodes the number of papers. The white dashed line corresponds to CP = CA. The white crosses
highlight the top 10 most cited papers by patents (Table A.2). (C) Overlap between the two lists of top cited papers by CP
and CA.
also show in Fig. 1A the distribution of CA, the total number of paper citations, and the power-law fit yields
exponent αA = 3.01. This suggests that despite paper citations are larger than patent citations—which
could simply due to the fact that there is a larger pool of papers than that of patents—they exhibit similar
speed of decay.
We further compare total patent and paper citations. Fig. 1B plots CP against CA in the form of heat
map, where the color encodes the frequency of papers. The map features a broad band with an upward
slope, indicating that papers under our consideration that have more paper citations in general tend to
attract more patent citations as well. The Spearman’s rank correlation coefficient between CP and CA is
0.228. Such a positive correlation persists (coefficient 0.251) if we consider all the 15, 678, 754 MEDLINE
papers that can be found in WoS. We also observe that the region of the highest density is located in the
lower left of the heat map, corresponding to the case where most papers have paper citations less than 100
and patent citations less than 10. The map indicates that the vast majority of papers have less patent
citations than paper citations, but 22, 736 (2.65%) papers exhibit the opposite, among which 8 of the top
10 papers with most patent citations are in this case. A total of 6, 166 (0.7%) papers are cited by patents
but got zero paper citation.
Are papers that are highly cited in the scientific community also highly cited in the patent sphere?
We quantified the extent of overlap between the two sets of top cited papers using a similarity measure.
Formally, let MP (MA) be the set of papers with the number of patent (paper) citations no less than
the threshold corresponding to a given percentile, and the similarity between MP and MA is defined as
s =
∣∣MP ∩MA∣∣ / ∣∣MP ∣∣, which measures the fraction of top cited papers by patents that are also top cited
by papers. Fig. 1C shows that similarity s steadily decreases as we increase the percentile. Only 18% of the
top 1% most cited papers by patents are also in the top 1% by the number of paper citations, indicating
a small overlap of papers that are highly cited in both the scientific and the technology community. This200
pattern is consistent if we consider only research articles (Fig. 1C) or papers in one filed (Fig. A.1A).
3.3. Delayed recognition papers
The previous section has examined the total number of citations measured at the end of our observation
period T = 2013, but how it reached to that number can be diverse. We now look at time-dependent citation
growth. From now on, we only restrict our analysis to the cohort of 852, 919 papers that (1) were published
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Figure 2: Beauty Coefficient BP and BA calculated based on patent and paper citation dynamics. (A) Distributions of BP
and BA. (B) Similarity of the sets of top SBs based on different percentiles.
from 1976 and onward, since patent citation data is available only starting from 1976, and (2) had at least
one paper citation (CA > 0), since we are interested in the comparison between cPt and c
A
t .
We first focus on a class of papers—the so-called “Sleeping Beauty” papers that lie dormant in a long
period of time after their publication and then suddenly become highly cited. This notion has been mostly
constrained within the scientific community, that is, citation curves based on which SBs are discovered are
derived from how many other scientific papers have cited the focal one. Recent work has started to extend
this notion to the technology domain (van Raan, 2017), and here we investigate whether there are also SBs
that are perceived as late boomer by the technology community.
To do so, we calculated the Beauty Coefficient based on the cPt and c
A
t curve of each paper (Ke et al.,
2015), denoted as BP and BA, respectively. Tables A.4 and A.5 report the top 10 SBs by BP and BA,
respectively. Fig. 2A, which plots the distributions of BP and BA, indicates that the extent of delayed
recognition of papers perceived by both the scientific and technology community spans three orders of
magnitude, similar to what has been observed before (Ke et al., 2015). Regarding individual papers, there
is a negligible correlation between their BP and BA values (Spearman correlation coefficient 0.09). There
is a low overlap of top SBs recognized by the two communities, as shown in Fig. 2B: only 5% of the top
1% SBs measured from patent citations also rank in the top 1% SBs measured from paper citations. This
observation still holds even if we consider only articles (Fig. 2B) or papers in one field (Fig. A.1B). These
results suggest different life-cycles of patent and paper citations.
3.4. Time-dependent citation accumulation
Having looked at a particular type of papers, we now characterize the temporal variation of citations.
To do so, we introduce the following parameters to describe a given citation dynamics curve ct:
1. tf = arg
{
mint
∑t
t′=0 ct > 0
}
. It measures the number of years taken to obtain the first citation;
2. tm = arg {maxt ct}. It is the number of years taken to obtain the maximum yearly citations;
3. I = 1 (∃t s.t. ct < ctm/2, t ∈ [tm + 1, L]). It indicates whether the yearly citations have decreased to
half of the maximum;
4. τ =
{
L− tm, I = 0
th − tm, I = 1
. The first case captures the number of years that the curve has stayed above
ctm/2 after reaching its maximum, given that the curve has not fallen below half of the maximum.
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The second case measures the number of years taken to fall below the half of the maximum, where th
is the time when ct drops below ctm/2 for the first time.
While the first two summarize how ct reaches the maximum, the latter two characterize how ct decrease
after that. As each paper is associated with two time-series, namely cPt and c
A
t , we further compute two
additional parameters: ∆tf = t
P
f − tAf and ∆tm = tPm − tAm, capturing how many years the first and the
maximum patent citation lag behind the paper citation case.
As illustration, Fig. 3 shows cPt and c
A
t for two papers. For the first paper (Bowie et al., 1990), which
was published in 1990, its yearly paper citations cAt reached its maximum quickly (t
A
f = 0, t
A
m = 1) and then
faded away steadily (IA = 1, τA = 3), whereas the patent citations c
P
t kept increasing for 20 years (t
P
f = 1,
tPm = 20) and then quickly died out (IP = 1, τP = 3), therefore ∆tf = 1 and ∆tm = 19. For the second
paper (Mosmann, 1983), published in 1983, its yearly paper citations reached the peak at the end of the
observation period (tAf = 1, t
A
m = 30, I
A = 0, τA = 0), whereas the patent citations climbed to the peak 16
years after publication, yielding ∆tm = −14.
We calculated the introduced parameters for each paper in our cohort. Fig. 4 presents the distributions
of these parameters across all papers, allowing us to probe overall patterns of their citation dynamics. First,
Fig. 4A, which shows the cumulative distribution of tPf and t
A
f , indicates that almost all papers obtained
their first paper citation during 5 years after publication, while only 30% of papers got cited by patents in 5
years. In general, we observe from Fig. 4B that first patent citation occurred after first paper citation was
obtained (∆tf > 0) for almost all papers, and the median lag is 7 years.
Focusing on tm, Fig. 4C indicates that the median number of years taken to reach maximum yearly
citations is 4 and 8 years for paper and patent citations, respectively. Fig. 4D shows that the majority
(78.9%) of papers obtained maximum yearly patent citations after the same event happened to paper
citations (∆tm < 0), and median lag is 6 years for those papers.
Focusing on how citations decrease after the peak, for only 0.6% papers, their patent citations have
not dropped below half of the maximum (IP = 0; Fig. 4E); and 9% for the paper citation case (IA = 0;
Fig. 4F). Fig. 4H indicates that most papers belonging to this category obtain maximum citations very
recently—within 3 and 7 years close to the end of the observation period for the patent and paper citation
case, respectively.
For the remaining 99.4% and 91% papers whose yearly patent and paper citations have decreased below
ctm/2, Fig. 4G shows that such decay is very rapid for both c
P
t and c
A
t , taking less than 3 and 8 years for
patent and paper citations, respectively.
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Figure 4: Distribution of parameters characterizing the temporal variation of patent and paper citations. (A) Cumulative
distribution function of the number of years taken to get the first patent (tPf ) and paper (t
A
f ) citation. (B) CDF of ∆tf = t
P
f −tAf .
(C) CDF of the number of years taken to reach to the maximum yearly patent (tPm) and paper (t
P
m) citations. (D) CDF of
∆tm = tPm − tAm. (E–F) The distribution of whether yearly citations have fallen to half of maximum. (G–H) CDF of τ given
I = 1 and I = 0.
4. Discussion
The increasing availability of large-scale datasets that systematically record how scholarly papers are
referenced and mentioned in different channels has opened new possibilities for searching for the broader
impact of research beyond the traditional scientific community. Previous studies have focused on news
media, clinical guidelines, policy documents, and the social Web. In this work, we looked at another
domain—patented technologies—that has received little attention so far in the literature, and studied the
technological impact of papers.
Based on a newly-created dataset that links millions of non-patent references made by U.S. patents to
MEDLINE papers, we compared citation statistics derived from patent references with traditional citations
from papers. We found that only a small fraction—4%—of papers ever got cited by patents. These papers
are mainly from Biochemistry, Molecular Biology, Allergy and Immunology, Cell Biology, and Chemistry,
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Figure A.1: Similarity between top papers in different fields. (A) top papers by CP and CA. (B) top papers by BP and BA.
and are published in leading biomedical journals. For these papers, there is a positive correlation between
the number of patent and paper citations, although the magnitude is low, leaving much variations to be
explained by other factors. The comparison between the curves of yearly patent and paper citations reveals
that the majority of papers got their first and maximum paper citation before obtaining patent citations,
highlighting different life-cycles of citation dynamics.
Future work is needed to uncover factors that explain the difference between patent and paper citations
and examine more closely the context of patent citations. E.g., what are the technological classes of citing
patents and what are the fields of cited papers? To what extent publicly-financed papers are cited by
private-sector patents? Answers to these questions would contribute further to the understanding of the
technological impact of scientific research.
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Table A.1: Field-specific rankings of top 10 journals by the total number of patent citations. We focus on the top 6 most cited
fields listed in Table 3. For each journal, we report the same set of statistics as in Table 3.
Biochemistry Science
Journal # C % C # P % P % Pub. Journal # C % C # P % P % Pub.
J. Biol. Chem 146, 369 24.26 34, 403 23.99 20.73 PNAS 211, 529 42.66 27, 268 47.79 23.72
Nucleic Acids Res. 62, 952 10.43 8, 165 5.69 22.12 Science 146, 331 29.51 12, 378 21.70 7.60
Biochemistry 46, 052 7.63 9, 795 6.83 16.05 Nature 117, 947 23.79 11, 508 20.17 11.53
Biochem. Biophys. Res. Commun. 35, 590 5.90 9, 013 6.29 12.00 Ann. N. Y. Acad. Sci. 10, 359 2.09 3, 372 5.91 7.15
Biochim. Biophys. Acta 25, 599 4.24 7, 443 5.19 8.08 Scientific American 2, 672 0.54 407 0.71 7.87
Anal. Biochem. 23, 093 3.83 4, 548 3.17 18.17 Nat. Mater. 1, 958 0.39 318 0.56 12.55
FEBS Lett. 22, 607 3.75 5, 803 4.05 13.42 Experientia 1, 630 0.33 589 1.03 2.88
Biochem. J. 17, 935 2.97 5, 318 3.71 9.91 Clinical Science 1, 184 0.24 395 0.69 5.60
Methods Enzymol. 17, 172 2.85 2, 893 2.02 15.79 Die Naturwissenschaften 494 0.10 105 0.18 2.06
FEBS J. 15, 671 2.60 4, 305 3.00 16.01 PloS ONE 336 0.07 236 0.41 0.29
Molecular Biology Allergy and Immunology
Journal # C % C # P % P % Pub. Journal # C % C # P % P % Pub.
EMBO J. 30, 232 10.72 4, 990 7.94 29.59 J. Immunol. 54, 523 22.43 11, 903 20.22 19.82
Mol. Cell. Biol. 26, 616 9.43 5, 241 8.34 24.78 J. Exp. Med. 29, 478 12.13 5, 002 8.50 22.59
Gene 25, 893 9.18 4, 206 6.69 24.91 Infect. Immun. 24, 129 9.93 6, 462 10.98 22.07
J. Mol. Biol. 24, 384 8.64 3, 991 6.35 13.56 J. Immunol. Methods 12, 066 4.96 2, 651 4.50 25.14
Nat. Med. 12, 958 4.59 1, 795 2.86 23.04 Eur. J. Immunol 10, 398 4.28 2, 407 4.09 17.38
Oncogene 11, 661 4.13 3, 187 5.07 19.70 Vaccine 8, 782 3.61 2, 361 4.01 14.88
Genes Dev. 9, 993 3.54 1, 892 3.01 27.42 Mol. Immunol. 5, 911 2.43 1, 086 1.84 16.72
Plant Molecular Biology 8, 593 3.05 1, 781 2.83 28.14 Immunol. Today 4, 871 2.00 681 1.16 23.23
Mol. Pharmacol. 6, 549 2.32 1, 741 2.77 16.39 Annu. Rev. Immunol. 4, 827 1.99 430 0.73 53.95
Mol. Microbiol. 6, 452 2.29 1, 846 2.94 16.41 Immunology 4, 068 1.67 1, 267 2.15 10.96
Cell Biology Chemistry
Journal # C % C # P % P % Pub. Journal # C % C # P % P % Pub.
Cell 61, 696 31.13 6, 265 14.92 37.77 J. Med. Chem. 69, 438 39.56 10, 795 24.51 42.95
Mol. Cell. Biol. 26, 616 13.43 5, 241 12.48 24.78 J. Am. Chem. Soc. 15, 990 9.11 4, 996 11.34 10.96
J. Cell Biol. 16, 627 8.39 3, 744 8.91 18.63 Bioorganic Med. Chem. Lett. 12, 341 7.03 3, 239 7.35 17.92
Plant Cell 8, 021 4.05 1, 383 3.29 27.59 J. Org. Chem. 9, 716 5.54 2, 993 6.80 13.98
Exp. Cell Res. 5, 527 2.79 1, 735 4.13 8.72 Chem. Pharm. Bull. 7, 306 4.16 2, 009 4.56 14.26
Plant Journal 5, 185 2.62 1, 117 2.66 19.59 J. Neurochem. 6, 328 3.60 2, 135 4.85 8.61
J. Cell. Physiol. 3, 833 1.93 1, 153 2.75 9.88 Angewandte Chemie 5, 168 2.94 1, 740 3.95 8.49
J. Cell Sci. 3, 822 1.93 1, 273 3.03 9.78 Bioorganic Med. Chem. 5, 083 2.90 1, 509 3.43 13.74
Cytometry 3, 186 1.61 737 1.75 26.26 Chem. Rev. 4, 663 2.66 630 1.43 25.70
J. Cell. Biochem. 2, 865 1.45 811 1.93 10.67 Chemistry & Biology 3, 926 2.24 649 1.47 22.31
Table A.2: Top 10 papers by total number of citations from USPTO-issued patents. For brevity, the “Author” column only
lists the first author.
PMID CP CA Author Title Year Journal
2315699 2748 385 JU Bowie Deciphering the message in protein sequences: tolerance to amino 1990 Science
acid substitutions
8844166 2014 125 Y Eshed Less-than-additive epistatic interactions of quantitative trait loci 1996 Genetics
in tomato
3285178 1938 44 E Lazar Transforming growth factor alpha: mutation of aspartic acid 47 1988 Mol. Cell. Biol.
and leucine 48 results in different biological activities
1699952 1770 92 WH Burgess Possible dissociation of the heparin-binding and mitogenic 1990 J. Cell Biol.
activities of heparin-binding (acidic fibroblast) growth factor-1
from its receptor-binding activities by site-directed mutagenesis
of a single lysine residue
1172191 1749 11000 G Ko¨hler Continuous cultures of fused cells secreting antibody of predefined 1975 Nature
specificity
9305836 1604 1053 IM Verma Gene therapy – promises, problems and prospects 1997 Nature
10631780 1499 78 J Skolnick From genes to protein structure and function: novel applications 2000 Trends Biotechnol.
of computational approaches in the genomic era
11325474 1473 276 SR Vippagunta Crystalline solids 2001 Adv. Drug Deliv. Rev.
2271534 1266 506 JA Wells Additivity of mutational effects in proteins 1990 Biochemistry
2231712 1235 35800 SF Altschul Basic local alignment search tool 1990 J. Mol. Biol.
Table A.3: Top 10 papers by total number of citations from papers.
PMID CP CA Author Title Year Journal
14907713 247 275527 OH Lowry Protein measurement with the Folin phenol reagent 1951 J. Biol. Chem.
5432063 942 198137 UK Laemmli Cleavage of structural proteins during the assembly of the head of 1970 Nature
bacteriophage T4
942051 568 145074 MM Bradford A rapid and sensitive method for the quantitation of microgram 1976 Anal. Biochem.
quantities of protein utilizing the principle of protein-dye binding
271968 1164 62573 F Sanger DNA sequencing with chain-terminating inhibitors 1977 PNAS
2440339 569 59607 P Chomczynski Single-step method of RNA isolation by acid guanidinium 1987 Anal. Biochem.
thiocyanate-phenol-chloroform extraction
388439 360 50513 H Towbin Electrophoretic transfer of proteins from polyacrylamide gels to 1979 PNAS
nitrocellulose sheets: procedure and some applications
13428781 51 41232 J Folch A simple method for the isolation and purification of total lipides 1957 J. Biol. Chem.
from animal tissues
7984417 158 38418 JD Thompson CLUSTAL W: improving the sensitivity of progressive multiple 1994 Nucleic Acids Res.
sequence alignment through sequence weighting, position-specific
gap penalties and weight matrix choice
2231712 1235 35800 SF Altschul Basic local alignment search tool 1990 J. Mol. Biol.
18156677 2 34459 GM Sheldrick A short history of SHELX 2008 Acta Crystallogr. A
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Table A.4: Top 10 delayed-recognition papers measured based on patent citations.
PMID BP BA CP CA Author Title Year Journal
6804947 1244 0 1180 96 S Rudikoff Single amino acid substitution altering antigen-binding specificity 1982 PNAS
1353878 1084 2 318 10 PC Huettner Neu oncogene expression in ovarian tumors: a quantitative study 1992 Mod. Pathol.
8404593 1013 1 325 28 B Freyschuss Induction of the estrogen receptor by growth hormone and 1993 Endocrinology
glucocorticoid substitution in primary cultures of rat hepatocytes
1463873 993 0 294 6 E Ha¨hnel Expression of the pS2 gene in breast tissues assessed by 1992 Breast Cancer Res. Treat.
pS2-mRNA analysis and pS2-protein radioimmunoassay
7507349 981 4 314 17 E Jacquemin Developmental regulation of acidic fibroblast growth factor 1993 Int. J. Dev. Biol.
(aFGF) expression in bovine retina
833720 939 116 1012 211 SM Berge Pharmaceutical salts 1977 J. Pharm. Sci.
8048062 935 0 323 82 ME Hahn Regulation of cytochrome P4501A1 in teleosts: sustained induction 1994 Toxicol. Appl. Pharmacol.
of CYP1A1 mRNA, protein, and catalytic activity by
2,3,7,8-tetrachlorodibenzofuran in the marine fish Stenotomus chrysops
8275492 922 0 322 172 I Husain Elevation of topoisomerase I messenger RNA, protein, and catalytic 1994 Cancer Res.
activity in human tumors: demonstration of tumor-type specificity
and implications for cancer chemotherapy
7741759 856 1 325 64 J George Pre-translational regulation of cytochrome P450 genes is responsible 1995 Biochem. Pharmacol.
for disease-specific changes of individual P450 enzymes among
patients with cirrhosis
6136691 808 30 131 16 P Svedman Irrigation treatment of leg ulcers 1983 Lancet
Table A.5: Top 10 delayed-recognition papers measured based on paper citations.
PMID BP BA CP CA Author Title Year Journal
3899825 47 553 18 11308 DR Matthews Homeostasis model assessment: insulin resistance and beta-cell 1985 Diabetologia
function from fasting plasma glucose and insulin concentrations
in man
728692 32 464 3 2683 RC Young A rating scale for mania: reliability, validity and sensitivity 1978 Br. J. Psychiatry
477100 11 448 2 1553 TA Gruen “Modes of failure” of cemented stem-type femoral components: 1979 Clin. Orthop. Relat. Res.
a radiographic analysis of loosening
976387 27 374 12 658 AJ Friedenstein Fibroblast precursors in normal and irradiated mouse 1976 Exp. Hematol.
hematopoietic organs
4028566 13 322 2 1167 Y Tegner Rating systems in the evaluation of knee ligament injuries 1985 Clin. Orthop. Relat. Res.
7018783 24 313 27 800 M Jarcho Calcium phosphate ceramics as hard tissue prosthetics 1981 Clin. Orthop. Relat. Res.
843571 31 287 4 13251 JR Landis The measurement of observer agreement for categorical data 1977 Biometrics
70454 13 267 2 89 GW Zack Automatic measurement of sister chromatid exchange frequency 1977 J. Histochem. Cytochem.
776922 22 241 8 264 ML Landsman Light-absorbing properties, stability, and spectral stabilization 1976 J. Appl. Physiol.
of indocyanine green
641088 20 220 4 569 GE Lewinnek Dislocations after total hip-replacement arthroplasties 1978 J. Bone Jt. Surg
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